Cabaletta Bio Inc. (CABA)
NASDAQ: CABAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CABA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $201.94M
- EPS (TTM)
- -$1.33
- Dividend yield
- None
- 52-week range
- 0.93 – 4.23
- Day range
- 0.93 – 1.03
- Volume / Avg
- 3.73M / 5.15M
- Beta
- —
- Shares outstanding
- 215.72M
52-week range
CABA stock today
Cabaletta Bio (CABA) closed at $0.9361 on Nov 20, down 7.32% (-$0.0739), versus the S&P 500's 3.70% decline. Shares are 77.9% below their 52-week high of $4.23, set on May 6, 2026 and 0.7% above the 52-week low of $0.93, near the bottom of the past year's range. CABA is down 57.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 55.0%.
Cabaletta Bio has posted a net loss over the last twelve months (EPS of -$1.33), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Cabaletta Bio
Company profileCabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Steven A. Nichtberger M.D.
- Headquarters
- Philadelphia, PA
- Employees
- 154
- IPO year
- 2019
- Website
- cabalettabio.com
Financial highlights
Full financialsCabaletta Bio reported a net loss of $167.9 million, compared with a loss of $115.9 million a year earlier. Diluted earnings per share came in at -$2.10.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-167.86M | $-115.86M | $-67.67M | $-52.98M | $-46.29M |
| EPS (diluted) | $-2.10 | $-2.34 | $-1.65 | $-1.81 | $-1.80 |
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$11.75+1155.21%
- Strong buy 1
- Buy 7
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.28 vs $-0.33
- Surprise
- +15.15%
CABA news
All CABA news- Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026NasdaqCABA, BF.A
- Cabaletta Bio Reports Positive Phase 1/2 Data For Rese-cel In Autoimmune Diseases; Stock UpNasdaqCABA, ET
- Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune DiseasesGlobeNewswire
- Cabaletta Bio, Inc. Reports Third Quarter 2026 Financial Results and $299.4 million Cash PositionNasdaq
- Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Cabaletta Bio to Participate in Upcoming Investor ConferencesGlobeNewswire
Cabaletta Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LCTXLineage Cell Therapeutics Inc. | 0.7719 | -5.87% | $195.26M | vs CABA |
| IPSCCentury Therapeutics Inc. | 1.17 | -11.74% | $211.56M | vs CABA |
| ARTVArtiva Biotherapeutics Inc. | 3.78 | -1.31% | $186.85M | vs CABA |
| ALLOAllogene Therapeutics Inc. | 0.6277 | -5.88% | $217.48M | vs CABA |
| IKTInhibikase Therapeutics Inc. | 1.32 | +1.54% | $185.16M | vs CABA |
| SCTXScribe Therapeutics Inc. | 12.07 | -8.70% | $228.58M | vs CABA |
| CGENCompugen Ltd. | 1.84 | -2.13% | $174.29M | vs CABA |
| AUTLAutolus Therapeutics plc ADR | 0.9073 | -7.38% | $241.65M | vs CABA |
Indexes, lists and sector
Cabaletta Bio stock FAQ
What is Cabaletta Bio's stock price today?
CABA last traded at $0.9361 as of Nov 20, 4:00 PM EST, down 7.32% on the day. Prices are delayed at least 15 minutes.
Who is Cabaletta Bio's CEO?
Dr. Steven A. Nichtberger M.D. is the chief executive officer of Cabaletta Bio Inc., which has about 154 employees.
What is the CABA 52-week high?
The 52-week high for CABA is $4.23 and the 52-week low is $0.93. The stock is currently 77.9% below its high.